Why Pain Is Worst at 3 a.m. | The Pained Brain, Chapter 7

Sleep deprivation · Insulin resistance

Sleep Deprivation and Insulin Resistance: Who to Screen in Pain Care

Screen for insulin resistance in chronic pain patients who report insomnia, frequent night waking or poor sleep quality, work night or rotating shifts, or take a nightly opioid. Fasting glucose and HbA1c alone miss the compensated phase, so the workup adds fasting insulin and triglycerides.

Four nights of restricted sleep measurably lower insulin sensitivity in healthy adults. In a pain population that sleeps in fragments, that makes the sleep history a metabolic screening trigger, not a lifestyle note.

The evidence on sleep deprivation insulin resistance is no longer epidemiology alone. Hyperinsulinemic clamp studies in healthy adults show whole-body insulin sensitivity falling within four to five nights of restriction, and the fall is larger when the sleep is also mistimed. For a physician managing chronic pain, the implication is operational: a patient who reports broken sleep is carrying a metabolic exposure that the usual fasting glucose will detect late, if at all.

The clinical argument comes from The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, in the chapter whose video is titled Why Pain Is Worst at 3 a.m. What follows translates it into screening terms: the effect sizes worth knowing, who meets a reasonable threshold for testing, what a result changes, and how to make it reproducible in a busy practice.

How much does sleep loss lower insulin sensitivity?

Magnitudes first. In 14 healthy adults, five nights of 4 hours against 8 lowered whole-body insulin sensitivity 25 percent and peripheral sensitivity 29 percent, with 24-hour urinary cortisol up 21 percent. In postmenopausal women, four nights of restriction cut clamp sensitivity 20 percent at the low insulin dose. Adipocytes biopsied from seven lean young adults after four nights at 4.5 hours needed nearly three times the insulin for half-maximal signaling, a 30 percent drop in total signaling response against a 16 percent drop in whole-body sensitivity. Pooled across 41 randomized trials of sleep restriction, the standardized effect on insulin sensitivity was -0.70.

Timing is a separate insult. Held to identical short sleep, men whose sleep was also shifted lost 58 percent of insulin sensitivity against 32 percent when aligned, and hsCRP rose 146 percent against 64. With the whole day moved 12 hours out of phase, glucose rose only 6 percent despite 22 percent more insulin, and 3 of 8 participants reached a prediabetic postprandial range. That compensation is the screening problem in miniature.

These are small samples of healthy volunteers over days, and the misalignment effect was significant in men only. None enrolled chronic pain patients. What they establish is mechanism and direction, and the population data supply the rest: each hour of sleep below seven carried 1.09 times the risk of type 2 diabetes across 482,502 participants, and night-shift work carried 1.30 times the hazard across ten cohorts.

Sleep deprivation insulin resistance: who meets the threshold for testing

Sleep disturbance and chronic musculoskeletal pain predict each other. In a 20-cohort meta-analysis of 208,190 adults, baseline sleep problems predicted incident pain at an odds ratio of 1.79, and baseline pain predicted incident sleep problems at 2.02. In daily reporting over six months in 801 adults, the sleep-to-pain path was the stronger one, and quality rather than duration carried it. Reasonable selection criteria include:

Chronic pain with insomnia, frequent nocturnal awakening or self-reported poor sleep quality.
Night-shift or rotating work, noting that the pooled diabetes association was significant in women and not in men, and that nurses showed no significant pain association once pooled.
Nightly opioid therapy: central sleep apnea affects about 24 percent of chronic opioid users, and in a multi-clinic cohort 58.8 percent of opioid-treated pain patients who completed a sleep study had sleep apnea, of whom only a quarter of the newly diagnosed received treatment.
Sedative-hypnotic use in older adults, for reasons covered under falls below.
Reported loss of strength or muscle, given that sarcopenia carried 1.26 times the odds of chronic pain in pooled adjusted data.

The social determinants are part of the selection, not an afterthought. Shift rosters, lit bedrooms and irregular schedules are occupational and economic exposures before they are behaviors. The practice-level criteria in selection criteria for testing map onto these groups directly.

What changes in management when sleep loss is found?

The first change is what gets measured. Fasting glucose and HbA1c alone will miss the compensated phase that the misalignment data describe, so a metabolic workup in this group reasonably adds fasting insulin and triglycerides through laboratory panels. Bioimpedance body composition documents lean and fat mass, which matters because overweight adults dieting on 5.5 hours of sleep lost 60 percent more lean mass than on 8.5, and because the NHANES analysis linking 10 percent more muscle to 11 percent lower HOMA-IR estimated muscle by impedance. Heart rate variability gives an autonomic baseline in a population in which six nights of restriction raised sympathetic activity.

The second change is sequencing. The practice position in the source material is that the sleep history is taken with the pain history, an apnea screen precedes the first opioid prescription, and a sleep study precedes dose escalation. That is a practice-reported position from our own population, not a trial outcome, and individual results vary. Polysomnography is outside the Measura [Cardiometabolic and Autonomic Health Analysis] library and is ordered separately; the value of pairing it with metabolic testing is that the same patient’s apnea, insulin and body composition are documented together rather than in three silos.

The third change is expectation setting. Cognitive behavioral therapy for insomnia produced a standardized 0.89 improvement in sleep and only 0.20 in pain across 12 trials, yet roughly a third of fibromyalgia patients achieved more than 30 percent pain reduction, and only the sleep-treated group held it at six months. Repeat metabolic measurement is how a clinician sees whether the terrain moved even when the pain score has not.

Pairing with fall prevention and cognitive assessment

The patients most likely to be sleeping badly on medication are also the patients at fall risk. Z-drug users carried 1.63 times the odds of fracture across 14 studies, and hip fracture risk ran roughly 2.4-fold for new users of both benzodiazepines and Z-drugs. Vestibular and balance testing belongs in the same encounter for older adults on sedative-hypnotics, and a cognitive assessment baseline gives the prescriber something to compare against when sedating regimens are reviewed. The integration model is laid out in cognitive assessment and fall prevention.

Documentation and workflow

Screening only works when it is reproducible. A standing order that fires on a documented sleep complaint in a chronic pain patient removes the dependence on one clinician remembering to ask; the template is in standing orders for screening. Record sleep as two fields, hours and awakenings, because fragmentation removed endogenous pain inhibition at matched sleep loss while consolidated restriction did not. Results belong in the structured record, and the annual wellness visit is a natural point to repeat the panel; see annual wellness visit integration. Where fall risk screening and cardiometabolic measures are tracked for MIPS or HEDIS, the same documentation supports those quality concepts without a separate workflow.

Dr. Padda directs the sharpest criticism at his own specialty: prescribing for pain while ignoring the clock was, in his words, a failure of care. The corrective is not a lecture on sleep hygiene. It is a measured baseline and a scheduled repeat. Unmeasured is unmanaged. The primary studies and their design limits are collected in the Chapter 7 companion supplement, the stress-axis companion is HPA axis dysfunction as a screening problem, and a patient-facing version is available to share.

Frequently asked questions

How quickly does sleep restriction affect insulin sensitivity?

Within days. Clamp studies in healthy adults show a 25 percent fall in whole-body insulin sensitivity after five nights of four hours and a 20 percent fall after four nights in postmenopausal women. A single night of total deprivation did not change inflammatory markers in pooled data, while three or more nights of about 4.5 hours raised interleukin-6 and CRP. Chronic patterns, not isolated nights, are the screening target. The clinical rationale for cardiometabolic testing.

Why is fasting glucose insufficient in these patients?

Because compensation hides the defect. In circadian misalignment, glucose rose only 6 percent while insulin rose 22 percent, and in a time-restricted eating crossover in men with prediabetes, insulin and insulin resistance improved while glucose did not change. A glucose-only protocol misclassifies both the exposure and the response. Adding fasting insulin and body composition captures the compensated phase. Interpreting the report.

Should opioid-treated patients be screened for sleep apnea before metabolic testing?

They are parallel questions, not sequential ones. Pooled referral data put central apnea near 24 percent in chronic opioid users, with risk concentrated at higher daily morphine-equivalent doses, and polysomnography is ordered separately. Metabolic and autonomic testing can proceed alongside it, so the same chart documents breathing, insulin and body composition together. Specialty applications in pain and primary care.

Does shift work justify metabolic screening on its own?

It is a reasonable contributing criterion. Night-shift work carried 1.30 times the hazard of type 2 diabetes across ten cohorts, significant in women, with a gradient by years of exposure. Nurses, the best-measured shift population, showed no significant pooled association with musculoskeletal pain, so the metabolic signal is stronger than the pain signal. Combine it with sleep complaints or pain rather than using it alone. Making screening reproducible with standing orders.

Can a lack of sleep cause diabetes?

Short sleep raises the risk. Across 482,502 participants, each hour of sleep below seven carried 1.09 times the risk of type 2 diabetes, and night-shift work carried 1.30 times the hazard across ten cohorts. Clamp studies show the mechanism: insulin sensitivity falls within four to five nights of restricted sleep, and when sleep was shifted out of phase, glucose rose only 6 percent while insulin rose 22 percent. That compensated phase is what screening should catch.

Does poor sleep make chronic pain worse?

Sleep and pain drive each other. In a 20-cohort meta-analysis of 208,190 adults, baseline sleep problems predicted new pain at an odds ratio of 1.79, and baseline pain predicted new sleep problems at 2.02. In six months of daily reporting from 801 adults, the sleep-to-pain path was the stronger one, and sleep quality mattered more than hours. Fragmented sleep also removed the body’s own pain inhibition.

Does the timing of sleep matter, or only the hours?

Timing matters on its own. Held to the same short sleep, men whose sleep was also shifted out of its normal window lost 58 percent of insulin sensitivity, against 32 percent when their sleep stayed aligned, and the inflammatory marker hsCRP rose 146 percent against 64. That is why night and rotating shift work belong in the selection criteria for metabolic testing, alongside insomnia and frequent waking.

Build sleep into your metabolic screening

Learn how the Measura protocol fits a pain or primary care practice, from selection criteria and standing orders to results in the chart.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Rao, M. N., Neylan, T. C., Grunfeld, C., Mulligan, K., Schambelan, M., & Schwarz, J.-M. (2015). Subchronic sleep restriction causes tissue-specific insulin resistance.
Broussard, J. L., Ehrmann, D. A., Van Cauter, E., Tasali, E., & Brady, M. J. (2012). Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study.
Zhu, B., Shi, C., Park, C. G., Zhao, X., & Reutrakul, S. (2019). Effects of sleep restriction on metabolism-related parameters in healthy adults: A comprehensive review and meta-analysis of randomized controlled trials.
Leproult, R., Holmbäck, U., & Van Cauter, E. (2014). Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss.
Santos, M., Gabani, F. L., de Andrade, S. M., Bizzozero-Peroni, B., Martínez-Vizcaíno, V., González, A. D., & Mesas, A. E. (2023). The bidirectional association between chronic musculoskeletal pain and sleep-related problems: a systematic review and meta-analysis.
Xie, F., Hu, K., Fu, R., Zhang, Y., Xiao, K., & Tu, J. (2024). Association between night shift work and the risk of type 2 diabetes mellitus: a cohort-based meta-analysis.
Wasef, S., Mir, S., Ryan, C., Waseem, R., Bellingham, G., Kashgari, A., Wong, J., & Chung, F. (2021). Treatment for patients with sleep apnea on opioids for chronic pain: results of the OpSafe trial.
Nedeltcheva, A. V., Kilkus, J. M., Imperial, J., Schoeller, D. A., & Penev, P. D. (2010). Insufficient sleep undermines dietary efforts to reduce adiposity.
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis.
Selvanathan, J., Pham, C., Nagappa, M., Peng, P. W. H., Englesakis, M., Espie, C. A., Morin, C. M., & Chung, F. (2021). Cognitive behavioral therapy for insomnia in patients with chronic pain – A systematic review and meta-analysis of randomized controlled trials.